What is the appropriate oseltamivir (Tamiflu) dosing for a child, including treatment and prophylaxis, based on age and weight?

Oseltamivir (Tamiflu) Dosing in Children

For children ≥12 months, use weight-based dosing: ≤15 kg = 30 mg, >15–23 kg = 45 mg, >23–40 kg = 60 mg, >40 kg = 75 mg, all given twice daily for 5 days; for infants <12 months, use 3 mg/kg per dose twice daily (or 3.5 mg/kg for 9–11 months), and for preterm infants, dose by postmenstrual age to avoid toxicity. 1, 2

Treatment Dosing (5 days, twice daily)

Children ≥12 Months (Weight-Based)

• ≤15 kg (≤33 lb): 30 mg twice daily = 5 mL of oral suspension 1, 2
• >15–23 kg (>33–51 lb): 45 mg twice daily = 7.5 mL of oral suspension 1, 2
• >23–40 kg (>51–88 lb): 60 mg twice daily = 10 mL of oral suspension 1, 2
• >40 kg (>88 lb): 75 mg twice daily = 12.5 mL of oral suspension 1, 2

Term Infants <12 Months (mg/kg-Based)

• 0–8 months: 3.0 mg/kg per dose twice daily 1, 2
• 9–11 months: 3.5 mg/kg per dose twice daily 1, 3
• Use the 6 mg/mL oral suspension with a calibrated 3–5 mL oral syringe for accurate measurement 1, 4

Preterm Infants (Postmenstrual Age-Based)

• <38 weeks PMA: 1.0 mg/kg twice daily 5, 1
• 38–40 weeks PMA: 1.5 mg/kg twice daily 5, 1
• >40 weeks PMA: 3.0 mg/kg twice daily 5, 1
• Postmenstrual age = gestational age at birth + chronological age 1, 4
• Using term-infant dosing in preterm infants causes toxic drug concentrations due to immature renal function 1, 4

Adolescents and Adults (≥13 Years)

• 75 mg twice daily for 5 days 1, 2

Prophylaxis Dosing (10 days, once daily)

Children ≥12 Months

• Use the same weight-based doses as treatment but once daily instead of twice daily 1, 2
• ≤15 kg: 30 mg once daily; >15–23 kg: 45 mg once daily; >23–40 kg: 60 mg once daily; >40 kg: 75 mg once daily 1, 2

Infants 3–11 Months

• 3 mg/kg once daily for 10 days 1, 4

Infants <3 Months

• Prophylaxis is not recommended unless the situation is judged critical due to limited safety data 5, 1

Adolescents and Adults (≥13 Years)

• 75 mg once daily for 10 days after exposure, or up to 6 weeks during community outbreak 1, 2

Renal Impairment Adjustments

• Creatinine clearance 10–30 mL/min (treatment): 75 mg once daily for 5 days (instead of twice daily) OR 30 mg once daily for 5 days 1, 2
• Creatinine clearance 10–30 mL/min (prophylaxis): 30 mg once daily for 10 days OR 75 mg every other day for 10 days (5 total doses) 5, 1
• Dose adjustment is mandatory when creatinine clearance falls below 60 mL/min to prevent drug accumulation 1, 2

Timing and Administration

• Initiate treatment within 48 hours of symptom onset for maximum effectiveness; starting within 12–24 hours provides substantially greater benefit (reduces illness by an additional 53.9–74.6 hours compared to starting at 48 hours) 1, 6
• Administer with food to significantly reduce nausea and vomiting, which occur in approximately 10–15% of patients 1, 6
• Complete the full 5-day course even if symptoms improve earlier; early discontinuation increases resistance risk 1

Formulations

• Oral suspension: 6 mg/mL concentration after reconstitution 1, 2
• Capsules: Available in 30 mg, 45 mg, and 75 mg strengths 1, 2
• If commercial suspension is unavailable, pharmacies can compound a 6 mg/mL suspension by opening capsules and mixing with simple syrup or Ora-Sweet SF 1

FDA Approval and Safety

• Treatment approval: FDA-approved for children as young as 2 weeks of age 1, 2
• Prophylaxis approval: FDA-approved starting at 1 year of age 1, 2
• When age-appropriate dosing is used, the safety profile in infants is comparable to older children 1, 4
• Most common adverse effects are gastrointestinal (nausea, vomiting, diarrhea) occurring in 10–15% of patients, typically resolving within 1–2 days 1, 6

Critical Dosing Pitfalls to Avoid

• Do NOT use the ≤15 kg categorical dosing (30 mg) for infants <12 months—that scheme applies only to children ≥12 months; infants require mg/kg dosing 1, 7
• Do NOT apply term-infant dosing to preterm infants—always calculate postmenstrual age and use PMA-based dosing to prevent toxicity 5, 1
• Do NOT confuse treatment dosing (twice daily) with prophylaxis dosing (once daily) 1, 7
• Do NOT use household spoons for measurement; always use a calibrated oral syringe for infants 1, 4
• Do NOT round doses inappropriately; calculate the exact mg/kg dose and measure the corresponding volume precisely 1, 4
• Do NOT delay treatment while awaiting laboratory confirmation during influenza season; clinical judgment is sufficient to initiate therapy 1, 7
• For extremely preterm infants (<28 weeks PMA), consult a pediatric infectious-disease specialist before initiating therapy 1, 7

Clinical Benefits

• Reduces illness duration by approximately 1–1.5 days (24–36 hours) compared to placebo 1
• Decreases secondary complications, especially acute otitis media, by approximately 44% 1, 6
• Rapidly decreases viral load in nasopharyngeal secretions within 1–2 days 8